Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial

Alice B. Gottlieb; Christopher Em Griffiths; Vincent Ho; M. Lahfa; Ulrich Mrowietz; Dédée F. Murrell; Ortonne Jp; Gail Todd; Robert Cherill; I. N. Marks; Shahram Emady‐Azar; C. Paul

doi:10.1111/j.1365-2133.2005.06661.x

Back

Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial

Article 2005 en

Abstract

1 min read

Oral pimecrolimus produces a dose-dependent reduction in psoriasis severity, with doses of 20 mg and 30 mg b.d. being the most effective and well tolerated.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article1995

Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: A randomized double‐blind trial

Peter Wutzler, De Clercq Erik, K Wutke, Inge Färber

Article2008

Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial

Sakari Reitamo, Phyllis I. Spuls, B. Sassolas, Morad Lahfa, A Claudy, Christopher Em Griffiths

Article2003

An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis

Mark Lebwohl, Enno Christophers, Richard G. Langley, Jean Paul Ortonne, Janet L. Roberts, Christopher Em Griffiths

Article2007

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS

J. A. Cohen, Marco Rovaris, Andrew Goodman, David Ladkani, Daniel Wynn, Massimo Filippi

Article2023

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

Jerry Bagel, April W. Armstrong, Richard B. Warren, Kim Papp, Diamant Thaçi, Alan Menter, Jennifer Clay Cather, Matthias Augustin, Lauren Hippeli, Carolin Daamen, Christopher Em Griffiths